UK markets close in 7 hours 19 minutes
  • FTSE 100

    7,000.09
    +4.01 (+0.06%)
     
  • FTSE 250

    23,008.08
    +131.07 (+0.57%)
     
  • AIM

    1,239.55
    +8.44 (+0.69%)
     
  • GBP/EUR

    1.1745
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.3866
    -0.0013 (-0.09%)
     
  • BTC-GBP

    28,680.79
    +1,753.82 (+6.51%)
     
  • CMC Crypto 200

    934.50
    +58.27 (+6.65%)
     
  • S&P 500

    4,401.46
    -20.84 (-0.47%)
     
  • DOW

    35,058.52
    -85.79 (-0.24%)
     
  • CRUDE OIL

    71.95
    +0.30 (+0.42%)
     
  • GOLD FUTURES

    1,801.90
    +2.10 (+0.12%)
     
  • NIKKEI 225

    27,581.66
    -388.56 (-1.39%)
     
  • HANG SENG

    25,375.79
    +289.36 (+1.15%)
     
  • DAX

    15,532.64
    +13.51 (+0.09%)
     
  • CAC 40

    6,556.35
    +24.43 (+0.37%)
     

Global COVID-19 Vaccines Market Opportunity Assessment and Forecast Report 2021-2026

·2-min read

Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

This report gives a COVID-19 disease overview, epidemiology overview, current marketed vaccines, unmet needs, pipeline assessment, and market outlook.

The publisher forecasts three different potential scenarios for the future use of COVID-19 vaccines:

  • The first scenario assumes that annual vaccination with a COVID-19 vaccine will be needed.

  • The second scenario assumes annual vaccination for the high-risk population of people 65 years of age and older, while everyone below 65 years of age will need a vaccine only every two years.

  • In the third scenario, the high-risk population of people 65 years of age and older will receive a COVID-19 vaccine every two years, while everyone below 65 years will need a vaccine only every five years.

Scope

This report includes:

  • Executive Summary

  • Disease Overview: History of the outbreak, Etiology and Pathophysiology

  • Epidemiology

  • Current Vaccination Options: Includes detailed product profiles with SWOT analysis

  • Unmet Need and Opportunities: Detailing the major unmet needs with significant KOL insights

  • Pipeline Assessment: Includes pipeline overview and detailed product profiles with SWOT analysis

  • R&D Strategies: Trends in Clinical Trial Design for COVID-19 Vaccines and Trends in Deal-Making

  • Market Outlook

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the 7MM COVID-19 vaccine.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global COVID-19 vaccine market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:

1. Executive Summary

2. Disease Overview

3. Epidemiology

4. Current Vaccination Options

5. Unmet Needs and Opportunities

6. Pipeline Assessment

7. R&D Strategies

8. Market Outlook

9. Appendix

Companies Mentioned

  • Pfizer

  • BioNTech

  • Moderna

  • AstraZeneca

  • Johnson & Johnson

  • Novavax

  • CureVac

  • Sanofi

  • GlaxoSmithKline

  • Arcturus

  • Medicago

  • Valneva

  • Inovio

For more information about this report visit https://www.researchandmarkets.com/r/48oajz

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting